Achilles Therapeutics plc
NASDAQ:ACHL
Overview | Financials
Company Name | Achilles Therapeutics plc |
Symbol | ACHL |
Currency | USD |
Price | 1.045 |
Market Cap | 42,936,857 |
Dividend Yield | 0% |
52-week-range | 0.63 - 1.76 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Iraj Ali |
Website | https://www.achillestx.com |
An error occurred while fetching data.
About Achilles Therapeutics plc
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD